LifespanningRx Review

What LifespanningRx charges

• Sermorelin: $270/mo — one-time purchase of a 1 month supply, in the seller's own words — "Single delivery of your selected duration. No subscription required." The 3 months supply lane on the same page is $590.00 in total, not $590.00 a month.
• NAD+: $225/mo — one-time purchase of a 1 month supply; the same page prices the identical supply at $191.25 on a lane it labels "1-month subscription SAVE 15%"
• Glutathione: $270/mo — one-time purchase of a 1 month supply; the same page prices the identical supply at $229.50 on a lane it labels "1-month subscription SAVE 15%"

One control, two answers, before any intake

Each product page carries a supply-duration control that switches between a one-month and a three-month supply and reprices the page as it does. A reader can see both figures without entering anything.

The control opens on the one-month option. Somebody who never touches it sees the one-month figure, which is what this row records for all three compounds.

Each duration is also offered as a subscription at fifteen percent less than the same duration bought once. The saving is measured against a price printed beside it on the same page, which is the only comparison a reader can actually check.

The three-month figure is a total for three months, not a rate per month. A hero banner offering two months with a third free is attached to the quarterly subscription program rather than to the one-time lane.

The company is named, the pharmacy is not

The terms name the corporation that operates the site, the state it is registered in and a street address, and the privacy policy repeats the same sentence. Florida is named as the governing law, with an arbitration clause beside it.

That is a real answer to who is charging the card, and it is not the answer most sellers here give.

The compounding pharmacy is a different question, and it goes unanswered. The product pages say a preparation is dispensed by a licensed compounding pharmacy in the United States and stop there.

Ten of the forty-five sellers compared here name the facility that fills an order; this is one of the thirty-five that do not. A named facility is one a reader can look up; a category is not.

No coverage list, and two claims to weigh yourself

Nothing on the site says which states it can ship to. The nearest sentence puts the question back on the reader, saying they must be legally permitted to use telehealth and prescription services where they live.

Twenty-four of the forty-five sellers here publish none, and this is one of them, so a reader outside a known-served state learns the answer only by starting an intake. Twenty-one publish a list of some kind.

The home page also carries a patient-count claim in the tens of thousands and a claim about the credentials of the clinicians behind it. Both are the company's own statements about itself, and neither can be checked from outside.

The prescription notice sits directly under the price rather than in a footer, which is a better placement than several sellers here manage.

Three compounds, and a catalog that reaches past them

Sermorelin, NAD+ and glutathione are the compounds this site tracks on this catalog, and all three sit on boards this site ranks.

The rest of the catalog runs to partner-supplied products and to items that are not medication at all, including a light-therapy device and a home test kit. Those are not compared here.

None of the three is an FDA-approved finished drug in the form sold here, and the product pages carry the prescription and consultation requirement themselves.

The figures for all three are whole dollars in the one-time lane, so nothing on this row depends on how a half-dollar amount is rounded on a page.

How we verified this

• Read all three product pages as rendered text, operating only the supply-duration control on the page and entering nothing.
• Recorded the one-month, one-time figure for each compound, because that is the option the control opens on.
• Checked the three-month figure against the one-month figure and confirmed the longer one is a total rather than a rate, then left it out of the row.
• Took the operating company, the state of incorporation and the address from the terms, and confirmed the privacy policy repeats them.
• Probed the host with a nonsense path in the same pass and confirmed it answers with its own not-found page rather than a live one.
• Read the terms, the privacy policy, the home page and all three product pages for any state coverage sentence, and found only the sentence quoted above.
• Searched the published federal warning-letter record for the named corporation across the years that record covers, and found no letter to it. That record does not include untitled letters.
• Re-counted the pharmacy-naming and no-state-list claims against the current roster rather than reusing an earlier figure.